Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151717 | 0.78 | HRH4 (0.37) | HRH4HRH3KDM4E | |
| SCHEMBL3373129 | 0.74 | ADH1A (0.42) | HRH4HRH3KDM4E | |
| SCHEMBL19102684 | 0.72 | HRH4 (0.37) | HRH4HRH3KDM4E | |
| SCHEMBL5253542 | 0.72 | ADH1A (0.44) | HRH4HRH3KDM4E | |
| SCHEMBL9949604 | 0.72 | HRH4 (0.37) | HRH4HRH3KDM4E | |
| SCHEMBL738707 | 0.72 | HRH4 (0.37) | HRH4HRH3KDM4E | |
| SCHEMBL4973138 | 0.72 | HRH4 (0.41) | HRH4HRH3KDM4E | |
| SCHEMBL14546899 | 0.72 | ADH1A (0.42) | HRH4HRH3 | |
| SCHEMBL14159145 | 0.72 | ADH1A (0.44) | HRH4HRH3KDM4E | |
| SCHEMBL9424888 | 0.72 | SIGMAR1 (0.50) | HRH4HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | HRH4 3699/4885HRH3 2787/4885DRD2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.